为何体外高过饱和度并不总能改善口服暴露

Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.

What the dissolution curve does not show: the mechanisms that determine whether a supersaturating formulation actually delivers oral exposure for poorly soluble drugs.

What Supersaturation Ratio Alone Does Not Tell You

In our previous blog, we compared the main solubility-enhancement strategies for BCS Class II and IV drugs by the development levers they actually change. This follow-up focuses on one of the most common failure modes within that framework: strong in vitro supersaturation that does not translate into meaningful oral exposure. Supersaturating formulations are designed to raise dissolved drug concentrations above the thermodynamic solubility limit, often producing dramatic in vitro gains relative to the crystalline reference. In early screening, those gains can look compelling. A high supersaturation ratio, however, does not by itself show whether the formulation will deliver better oral exposure.

The reason is straightforward: oral absorption depends on more than the peak concentration reached in a dissolution test. The formulation also has to maintain useful dissolved drug under the changing conditions of the GI tract, resist premature precipitation, and keep the drug available for permeation long enough to support uptake. While the standard in vitro dissolution test (e.g. biorelevant) only correlates to the solubilizing but not the adsorption process, the in vivo is a dynamic process which involves near-simultaneous drug dissolution and permeation. Thus, a  strong in vitro supersaturation signal can therefore coexist with disappointing in vivo performance.

This is the central development challenge for supersaturating formulations. The question is not only how much drug enters solution, but whether that dissolved concentration survives in a form and for a duration that actually matters for absorption. Once the problem is framed that way, the limitation of relying on supersaturation ratio alone becomes much clearer.

Itraconazole: A Case Study in Supersaturation That Does Not Survive

Itraconazole is a useful model for this problem. As a weak base with pKa values around 2 and 3.7, it dissolves readily in the acidic stomach, and an ASD can generate strong supersaturation under those conditions. But once the drug enters the intestine and the pH rises to 6 to 7, its thermodynamic solubility drops sharply. Without effective precipitation inhibition, the supersaturated concentration can collapse before meaningful absorption occurs.

Two-stage dissolution studies make the point clearly. For an HPMCAS-based ASD formulation, although the drug is released only partially in the simulated gastric fluid (SGF), substantial release is achieved when the system shifts from SGF to the fasted simulated intestinal fluid (FaSSIF) The polymer then retains the supersaturation level after this pH transition for over 2hrs, while a comparable formulation with another polymer cannot effectively prevent the immediate precipitation . [1] The difference is visible once the test reflects what happens between the stomach and the intestine.

Itraconazole illustrates a broader lesson. The formulation can perform exactly as designed in the screening environment and still fail under the conditions that determine oral absorption. The gap is not visible in the supersaturation ratio alone. It only becomes visible when the test captures what happens after the drug leaves the stomach.

Why It Happens: Three Mechanisms Behind the Gap

The itraconazole case is one instance of a general pattern. When strong in vitro supersaturation fails to translate in vivo, one or more of three mechanisms is usually responsible.

1. The rate of supersaturation generation is too fast.

A supersaturating formulation can fail when dissolved drug concentration rises faster than the system can stabilize it. A rapid burst of dissolution may produce a high peak concentration, but it can also increase the driving force for nucleation and shorten the lifetime of the supersaturated state. In practice, the fastest-dissolving formulation is not always the one that delivers the greatest useful dissolved exposure over time. This relationship has been demonstrated experimentally, including in work by Sun and Lee showing that faster supersaturation generation can accelerate precipitation rather than improve sustained dissolved concentration.[2]
2. The GI environment behaves differently than the dissolution vessel.

Standard dissolution uses a single medium at a fixed pH. The gastric-to-intestinal transition is not only a pH shift. In the intestine, bile salts and phospholipids can change solubilization and precipitation behavior, particularly for lipophilic poorly soluble drugs. As a result, a supersaturated state that looks robust in a simple dissolution medium may behave very differently in biorelevant intestinal conditions.
3. High apparent concentration does not equal available concentration.

When concentration exceeds the amorphous solubility, the system can undergo liquid-liquid phase separation, forming drug-rich nanodroplets. Transmembrane flux is governed by molecularly dissolved drug, not by total apparent concentration.[3] Without techniques that separate the two, dissolution data can overstate how much drug is actually available for absorption.

Each mechanism has the same structure: a property that matters in vivo is not captured by the standard in vitro measurement.

What to Evaluate Beyond the Supersaturation Ratio

Development teams can narrow the gap by expanding what they measure early, before the program commits to a formulation:

• ### Design formulation to control supersaturation.

Design formulation to ensure the simultaneous release of drug and supersaturation maintainers (e.g. polymers, surfactant etc.). Conduct prolonged biorelevant dissolution (e.g. 2-3hrs) to evaluate the in vitro kinetic solubility and supersaturation. Use biorelevant media with pH transition. A two-stage test shifting from simulated gastric to intestinal fluid reveals precipitation risk that single-stage dissolution misses. This is especially critical for weak bases.
* ### Distinguish free drug from colloidal species.

Ultracentrifugation, light scattering, or NMR-based methods can separate molecularly dissolved drug from drug-rich nanodroplets and prevent systematic overestimation of formulation performance.

What Comes Next

The next article in this series will focus on solid-form instability: how polymorph changes, salt disproportionation, and recrystallization during manufacturing and storage can undermine solubility enhancement strategies that appeared well-chosen at the start of development.

How Crystal Pharmatech Can Help

Crystal Pharmatech helps development teams evaluate supersaturating formulations under conditions that reflect in vivo performance, not just screening performance. Our capabilities include biorelevant dissolution with pH transition and precipitation monitoring, characterization of liquid-liquid phase separation and colloidal species, and polymer selection for precipitation inhibition. Furthermore, we can evaluate in vitro simultaneous dissolution and permeation by our Pion system (at CP-NJ).

References

1. Chen Y, Liu C, Chen Z, et al. Polymer-surfactant system based amorphous solid dispersion: precipitation inhibition and bioavailability enhancement of itraconazole. Pharmaceutics. 2018;10(2):53.
2. Sun DD, Lee PI. Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation. Mol Pharm. 2013;10(11):4330–4346.
3. Indulkar AS, Gao Y, Raina SA, et al. Exploiting the phenomenon of liquid-liquid phase separation for enhanced and sustained membrane transport of a poorly water-soluble drug. Mol Pharm. 2016;13(6):2059–2069.

Read the original article and source figures